Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular) (ALYCEmolecular)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03859544|
Recruitment Status : Recruiting
First Posted : March 1, 2019
Last Update Posted : March 1, 2019
Central nervous system lymphoma (PCNSL) is a diffuse large B cell lymphoma (DLBCL) entity with a particularly poor prognosis (median survival less than 3 years). They are still poorly characterized biologically, largely because of their rarity (300 cases / year in France) and the difficulty for obtaining a material of sufficient quality and quantity. It is nevertheless assumed that their pathophysiology is particular, since they develop exclusively in an immunological sanctuary, and that they present some characteristic molecular abnormalities (mutation of MYD88 or TBL1XR1 for example).
A collection of 74 PCNSLs has created, clinically annotated, from which frozen material is available in addition to the material fixed and included in paraffin (cohort ALYCE). Informed consent was gathered for all patients. Comparative Genomic Hybridization-array analysis of this cohort has already revealed abnormalities associated with a poor prognosis (unpublished data). The objective of this study is to complete this analysis by sequencing a panel of 96 mutant genes recurrently in DLBCLs and PCNSLs, and the molecular determination of the original cell by the (RT-MLPA) Reverse Transcriptase-Multiplex Ligation-dependent Probe Amplification technique.
The integration of genetic, molecular and transcriptomic data may define prognostic markers and open perspectives for translational research in PCNSL.
|Condition or disease||Intervention/treatment|
|Central Nervous System Lymphoma||Other: Retrospective study|
|Study Type :||Observational|
|Estimated Enrollment :||74 participants|
|Official Title:||Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular)|
|Actual Study Start Date :||January 1, 2016|
|Estimated Primary Completion Date :||January 1, 2020|
|Estimated Study Completion Date :||January 1, 2020|
- Other: Retrospective study
Retrospective study to search mutations associated with Central nervous system lymphoma and study of the prognostic impact (overall survival and progression-free survival) of these mutations.
- Progression free survival [ Time Frame: Up to 48 months ]Analysis of progression-free survival correlated with genomic data and mutation data
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03859544
|Contact: Hervé GHESQUIERES, Premail@example.com|
|Contact: Pierre SUJOBERT, Drfirstname.lastname@example.org|
|Service d'hématologie biologique - Centre Hospitalier Lyon Sud - HCL||Recruiting|
|Pierre-Bénite, France, 69495|
|Contact: Pierre SUJOBERT, Dr email@example.com|